News & Trends - Pharmaceuticals
Down-scheduling of sumatriptan and zolmitriptan to treat migraines
Pharma News: The Pharmacy Guild of Australia has welcomed the decision to down- schedule sumatriptan and zolmitriptan to S3, or pharmacist-only medicines.
Sumatriptan and zolmitriptan are used to treat migraines and the National President of the Pharmacy Guild, George Tambassis, said the decision to down-schedule the medicines was a good outcome for patients.
“Patients don’t know when a migraine is coming on and so have had to try to manage their medicines by having a prescription on hand in case they needed to fill it,” he said.
“This very sensible decision by the delegate means that patients who have a stable, well-established pattern of symptoms, will be able to access sumatriptan and zolmitriptan for the acute relief of migraine when and where they need it.
Register FREE & join 22,000+ industry professionals in reading the latest industry news & engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.
“Importantly, being pharmacist-only medicines will ensure that patients receive the counselling and advice to ensure they are taking the medicine appropriately.
“In its decision the TGA pointed to the fact that the ‘access controls in place for a Schedule 3 medicine are appropriate and sufficient to mitigate the misuse’ of these medicines.”
News & Trends - Pharmaceuticals
Federal Health Minister succumbs to pressure, commits to extra meeting to clear PBAC backlog
Pharma News: The Minister for Health and Aged Care, Mark Butler MP, has confirmed that the Pharmaceutical Benefits Advisory Committee […]
MoreNews & Trends - MedTech & Diagnostics
Medtech company partners with Aussie researchers in AI technology for GI cancer detection
MedTech & Diagnostics News: To develop a next-generation gastrointestinal (GI) flexible endomicroscope equipped with edge-artificial intelligence (AI) technology, Monash University’s […]
MoreNews & Trends - Pharmaceuticals
Local oncologists first to enrol prostate cancer patients in phase 3 theranostics trial
Pharma News: GenesisCare oncologists have achieved a significant milestone, becoming the first to enrol and deliver patient treatment in a […]
MoreHuman Resources
Ipsen’s culture of ‘collaboration and diversity’ earns Great Place to Work certification
Ipsen Australia and New Zealand has announced its certification as a Great Place to Work in 2024, joining 11 other […]
More